Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic autoimmune neuropathy and often responds to corticosteroids, plasmapheresis, and intravenous immunoglobulin (IVIg).¹ The only US Food and Drug Administration-approved, and the most commonly applied therapy, is IVIg, which, at 2 g/kg followed by 1 g/kg every 3–4 weeks, has been shown to prevent relapses and maintain stability in 75% of patients.² Subcutaneous immunoglobulin (SCIg), an alternative route of IgG administration, is approved for IgG replacement therapy in primary immunodeficiency,³ but whether or not it has an effect in balancing immune dysregulation in autoimmune diseases, as IVIg does,⁴ has not been formally tested.

中文翻译：

---

皮下IgG治疗慢性炎性脱髓鞘性多神经病

慢性炎性脱髓鞘性多发性神经病（CIDP）是最常见的慢性自身免疫性神经病，通常对皮质类固醇，血浆置换和静脉内免疫球蛋白（IVIg）产生反应。¹唯一获得美国食品和药物管理局批准且最常用的治疗方法是IVIg，已证明IVIg可以预防复发并维持其稳定性，IVIg剂量为2 g / kg，随后每3–4周1 g / kg。 75％的患者。²皮下免疫球蛋白（SCIg）是IgG的另一种给药途径，已被批准用于原发性免疫缺陷的IgG替代疗法^3，但它是否像IVIg一样具有平衡自身免疫疾病免疫失调的作用⁴尚未正式经过测试。